Ranked #1 Children's Hospital by U.S. News & World Report
MyPatients provides referring primary care providers with secure access to their patients’ information.
Boston Children's has launched the world's 1st program dedicated to offering hand transplants to children who qualify.
Innovation insider is a semi-monthly e-newsletter analyzes innovations at Boston Children’s, other academic medical centers and from industry.
Read the latest blog by a Boston Children's doctor, clinician or staff member.
Support the hospital with a donation that helps kids get the care they need.
Principal Investigator: Maureen Jonas, MD
Department: Gastroenterology, Center for Childhood Liver Disease
Protocol Status: Open for Recruitment
Trial Description: This is a study of the use of entecavir, an oral medication, in children with chronic hepatitis B who have abnormal liver enzymes. This medication is already approved for adults with chronic hepatitis B. This research will determine if the drug is safe and effective for children and adolescents. This is a randomized trial, which means that some subjects will receive active drug and some will receive placebo. After 48 weeks, if the hepatitis B has not responded, all subjects will be able to get study drug (entecavir).
Recruitment Info: The patient must be less than 18 years of age, have chronic hepatitis B and have abnormal liver enzymes. Further details are available on request.
PI contact: Maureen Jonas, MD
PI phone: Center for Childhood Liver Disease, 617-355-5837
The future of pediatrics will be forged by thinking differently, breaking paradigms and joining together in a shared vision of tackling the toughest challenges before us.”